BioXcel Therapeutics Inc (NASDAQ:BTAI) Expected to Post Earnings of -$0.52 Per Share

Equities research analysts forecast that BioXcel Therapeutics Inc (NASDAQ:BTAI) will announce earnings per share of ($0.52) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for BioXcel Therapeutics’ earnings. BioXcel Therapeutics posted earnings of ($0.19) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 173.7%. The business is scheduled to announce its next earnings report on Wednesday, August 14th.

On average, analysts expect that BioXcel Therapeutics will report full year earnings of ($2.19) per share for the current financial year. For the next year, analysts expect that the business will post earnings of ($3.01) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow BioXcel Therapeutics.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02.

A number of equities research analysts recently commented on BTAI shares. Canaccord Genuity set a $21.00 price target on shares of BioXcel Therapeutics and gave the stock a “buy” rating in a report on Friday, March 8th. HC Wainwright set a $25.00 price target on shares of BioXcel Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 28th. ValuEngine raised shares of BioXcel Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 11th. Finally, Zacks Investment Research raised shares of BioXcel Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Friday, May 31st.

A hedge fund recently bought a new stake in BioXcel Therapeutics stock. Creative Planning acquired a new stake in BioXcel Therapeutics Inc (NASDAQ:BTAI) in the first quarter, according to its most recent filing with the SEC. The fund acquired 30,550 shares of the company’s stock, valued at approximately $302,000. Creative Planning owned approximately 0.20% of BioXcel Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:BTAI traded up $0.03 during mid-day trading on Wednesday, reaching $10.52. The company had a trading volume of 1,799 shares, compared to its average volume of 32,480. The company has a current ratio of 5.59, a quick ratio of 5.59 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $171.38 million, a price-to-earnings ratio of -7.83 and a beta of 3.45. The company has a 50-day simple moving average of $10.87. BioXcel Therapeutics has a one year low of $2.41 and a one year high of $14.79.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Recommended Story: What is a Futures Contract?

Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.